AKT1 and colorectal carcinoma: To seek whether targeting the PI3K-AKT/HK2 pathway also abrogates the tumorigenic propensity of CRC cells, we used a selective pharmacologic inhibitor of PI3K (LY294002) to study colony formation and cell proliferation over time.